BioBlock® nasal spray

BioBlock®, a nasal spray containing bovine antibodies against SARS-CoV-2, is produced in collaboration with Estonian scientists and entrepreneurs with the intention to prevent the spread of the virus.

The concept of colostrum-derived nasal spray is led by Professor Mart Ustav.

Concept of manufacturing

Development of antibodies

2. Antibodies transferred to colostrum

3. Separation of whey from colostrum

4. Antibodies are purified, pasteurized and sterilized

5. Antibody containing solution is formulated and dispensed into nasal spray bottles

How BioBlock® works?

Deposition of BioBlock® intranasally and orally

The antibodies form a protective layer on the mucosal epithelium

Viral particles that enter the upper respiratory tract are neutralized by the antibodies on the mucous

How to use BioBlock®?

Spray 2 times into each nostril, 3-4 times a day, before and after visiting crowded places.

We recommend to use the spray again after blowing the nose.

BioBlock® is effective on the nasal mucosa up to 4 hours and one bottle contains 150 spray doses.

Research

BioBlock efficiency on Delta and Omicron

Colostrum immunoglobulin preparation blocks SARS-CoV-2 Spike protein binding to ACE2 receptor in ELISA assay

Immunoflobulins from immunized cows inhibit SARS-CoV-2 virus entry to Vero E6 cells in the cytopathic effect neutralization assay

Colostrum derived immunoglobulins from immunized cows neutralize pseudovirus displaying different Spike proteins of currently circulating SARS-CoV-2 variants

Syrian Golden Hamsters (n=8) were administered BioBlock intranasally at two different concentrations (0.1 mg/mL and 0.2 mg/mL), followed by an infection of SARS-CoV-2 virus (10⁵ pfu). After 4 days the lung viral titer was determined. BioBlock antibody solution reduces viral load even after a single intranasal administering dose.

Antibodies in BioBlock remain on the human nasal mucosa at least 4 hours after administration

Eight people were administered 400 µl of BioBlock nasal spray solution. Filter paper piecer (15 µl) were placed onto the nasal mucosa and the concentration of bovine antibodies was measured.

Publications and patent

Kangro K, Kurašin M, Gildemann K, Sankovski E, Žusinaite E, et al. (2022) Bovine colostrum-derived antibodies against SARS-CoV-2 show great potential to serve as prophylactic agents. PLOS ONE 17(6): e0268806. Read the paper here.

A USPTO patent application (No. 63/150.833) has been submitted by the product developers.